Ruilin Tian

Dr. Ruilin Tian

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2021 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
RTRuilin Tian
Ruilin Tian
AAAnthony Abarientos
Anthony Abarientos
JHJason Hong
Jason Hong
SHSayed Hadi Hashemi
Sayed Hadi Hashemi
RYRui Yan
Rui Yan
MKMartin Kampmann
Martin Kampmann

13 January 2022 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
ASAvi J. Samelson
Avi J. Samelson
QTQuang Dinh Tran
Quang Dinh Tran
RRRémy Robinot
Rémy Robinot
LCLucia Carrau
Lucia Carrau
VRVeronica V. Rezelj
Veronica V. Rezelj
MKMartin Kampmann
Martin Kampmann

26 June 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
PRPoornima Ramkumar
Poornima Ramkumar
AAAnthony B. Abarientos
Anthony B. Abarientos
RTRuilin Tian
Ruilin Tian
MSMeghan Seyler
Meghan Seyler
JLJaime T. Leong
Jaime T. Leong
MKMartin Kampmann
Martin Kampmann
Cancer cells commonly develop resistance to immunotherapy by loss of antigen expression. Combinatorial treatments that increase levels of the target antigen on the surface of cancer cells have the potential to restore efficacy to immunotherapy. Here, we use our CRISPR interference– and CRISPR activation–based functional genomics platform to systematically identify pathways controlling cell surface expression of the multiple myeloma immunotherapy antigen B-cell maturation antigen (BCMA). We discovered that pharmacologic inhibition of HDAC7 and the Sec61 complex increased cell surface BCMA, including in primary patient cells. Pharmacologic Sec61 inhibition enhanced the antimyeloma efficacy of a BCMA-targeted antibody-drug conjugate. A CRISPR interference chimeric antigen receptor T cells (CAR-T cells) coculture screen enabled us to identify both antigen-dependent and antigen-independent mechanisms controlling response of myeloma cells to BCMA-targeted CAR-T cells. Thus, our study shows the potential of CRISPR screens to uncover mechanisms controlling response of cancer cells to immunotherapy and to suggest potential combination therapies.

1 March 2021 in Molecular Cell
Verified
Journal Article
Closed access
FHFrances V. Hundley
Frances V. Hundley
NDNerea Sanvisens Delgado
Nerea Sanvisens Delgado
HMHarold C. Marin
Harold C. Marin
KCKaili L. Carr
Kaili L. Carr
RTRuilin Tian
Ruilin Tian
DTDavid P. Toczyski
David P. Toczyski

18 April 2023 in Cell Genomics
Verified
Journal Article
Open access
KLKun Li
Kun Li
MOMiao Ouyang
Miao Ouyang
JZJiangshan Zhan
Jiangshan Zhan
RTRuilin Tian
Ruilin Tian
While our knowledge of gene expression in different human cell types is rapidly expanding with advances in transcriptomic profiling technologies, the next challenge is to understand gene function in each cell type. CRISPR-Cas9-based functional genomics screening offers a powerful approach to determine gene function in a high-throughput manner. With the maturation of stem cell technology, a variety of human cell types can be derived from human pluripotent stem cells (hPSCs). Recently, the integration of CRISPR screening with hPSC differentiation technologies opens up unprecedented opportunities to systematically examine gene function in different human cell types and identify mechanisms and therapeutic targets for human diseases. This review highlights recent progress in the development and applications of CRISPR-Cas9-based functional genomics screening in hPSC-derived cell types, discusses current challenges and limitations, and outlines future directions for this emerging field.

16 November 2022 in Cell Discovery
Verified
Journal Article
Open access
PDF file
YSYaping Shen
Yaping Shen
JWJianhui Wang
Jianhui Wang
YLYaning Li
Yaning Li
YZYuanyuan Zhang
Yuanyuan Zhang
RTRuilin Tian
Ruilin Tian
RYRenhong Yan
Renhong Yan